Current Report Filing (8-k)
November 19 2018 - 9:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 13, 2018
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50679
|
|
77-0487658
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650)
327-3270
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former, address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR 240.14d2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR 240.13e4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On November 13, 2018, Robert S. Fishman, M.D. informed Corcept
Therapeutics Incorporated of his resignation as Chief Medical Officer, effective January 31, 2019 (the Termination Date). It is expected that Dr. Fishman will continue to serve as Chief Medical Officer through the Termination
Date to assist with the transition of his responsibilities.
Forward-Looking Statements
Statements in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, are based on our current plans and expectations and are subject to risks and uncertainties that might cause actual results to differ materially from those such statements express or
imply. These risks are set forth in our Securities and Exchange Commission (SEC) filings, which are available at our website and the SECs website. In this Current Report, forward looking statements include those concerning Dr.
Fishmans continued service through the Termination Date and assistance with the transition of his responsibilities. We disclaim any intention or duty to update forward-looking statements made in this Current Report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
CORCEPT THERAPEUTICS INCORPORATED
|
|
|
By:
|
|
/s/ G. Charles Robb
|
|
|
Name:
|
|
G. Charles Robb
|
|
|
Title:
|
|
Chief Financial Officer and Secretary
|
Date: November 19, 2018
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Sep 2023 to Sep 2024